"Superbugs bunny" outsmarts our immune defense

ChemMedChem

Volumn 3, Issue 8, 2008, Pages 1173-1177

  Haebich, Dieter ^a   Von Nussbaum, Franz ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Antibiotics; Carotenoids; Cholesterol; Dehydrosqualene synthase; Staphylococcus aureus; Staphyloxanthin

Indexed keywords

CHOLESTEROL; STAPHYLOXANTHIN; VIRULENCE FACTOR; XANTHOPHYLL;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOSYNTHESIS; CHEMISTRY; COLOR; DRUG EFFECT; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

CHOLESTEROL; COLOR; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMMUNE SYSTEM; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE FACTORS; XANTHOPHYLLS;

EID: 54449089765     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200800171     Document Type: Short Survey

References (50)

1. A. El-Agamey, G. M. Lowe, D. J. McGarvey, A. Mortensen, D. M. Phillip, T. G. Truscott, A. J. Young, Arch. Biochem. Biophys. 2004, 430, 37-48.
2. a) J. F. Barrett, Expert Opin. Ther. Targets 2004, 8, 515-519;
3. b) C. D. Salgado, B. M. Farr, D. P. Calfee, Clin. Infect. Dis. 2003, 36, 131-139.
4. R. M. Klevens, M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, S. K. Fridkin, JAMA J. Am. Med. Assoc. 2007, 298, 1763-1771.
5. a) C. Walsh, Nature 2000, 406, 775-778;
6. b) G. D. Wright, Curr. Opin. Chem. Biol. 2003, 7, 563-569;
7. c) M. N. Alekshun, S. B. Levy, Cell 2007, 128, 1037-1050.
8. a) H. Pearson, Nature 2002, 418, 469;
9. b) Community-associated methicillin-resistant S. aureus USA300: A. D. Kennedy, M. Otto, K. R. Braughton, A. R. Whitney, L. Chen, B. Mathema, J. R. Mediavilla, K. A. Byrne, L. D. Parkins, F. C. Tenover, B. N. Kreiswirth, J. M. Musser, F. R. DeLeo, Proc. Natl. Acad. Sci. USA 2008, 105, 1327-1332;
10. c) S. J. Projan, P. A. Bradford, Curr. Opin. Microbiol. 2007, 10, 441-446.
11. 10th Annual Superbugs and Superdrugs Conference, April 9 - 10, 2008, London (UK).
12. For a number of recently investigated antibiotic lead structures, see: a) R. H. Baltz, V. Miao, S. K. Wrigley, Nat. Prod. Rep. 2005, 22, 717-741;
13. b) S. Walker, J. Helm, Y. Hu, L. Chen, Y. Rew, D. L. Boger, Chem. Rev. 2005, 105, 449-476;
14. c) D. Häbich, F. von Nussbaum, ChemMedChem 2006, 1, 951-954;
15. d) B. Hinzen, S. Raddatz, H. Paulsen, T. Lampe, A. Schumacher, D. Häbich, V. Hellwig, J. Benet-Buchholz, R. Endermann, H. Labischinski, H. Brötz-Oesterhelt, ChemMedChem 2006, 1, 689-693;
16. e) J.-M. Campagne, Angew. Chem. 2007, 119, 8700-8704;
17. Angew. Chem. Int. Ed. 2007, 46, 8548-8552;
18. f) F. von Nussbaum, S. Anlauf, J. Benet-Buchholz, D. Häbich, J. Köbberling, L. Musza, J. Telser, H. Rübsamen-Waigmann, N. A. Brunner Angew. Chem. 2007, 119, 2085-2088;
19. Angew. Chem. Int. Ed. 2007, 46, 2039-2042;
20. g) F. von Nussbaum, S. Anlauf, C. Freiberg, J. Benet-Buchholz, J. Schamberger, T. Henkel, G. Schiffer, D. Häbich, ChemMedChem 2008, 3, 619-626.
21. a) S. J. Projan, Antimicrob. Agents Chemother. 2007, 51, 1133-1134;
22. b) S. J. Projan, Drug Discovery Today 2008, 13, 279-280;
23. c) C. Walsh, Nat. Rev. Microbiol. 2003, 1, 65-70;
24. d) F. von Nussbaum, M. Brands, B. Hinzen, S. Weigand, D. Häbich, Angew. Chem. 2006, 118, 5194-5254;
25. Angew. Chem. Int. Ed. 2006, 45, 5072-5129.
26. R. F. Service, Science 2004, 303, 1796-1799.
27. C.-I. Liu, G. Y. Liu, Y. Song, F. Yin, M. E. Hensler, W.-Y. Jeng, V. Nizet, A. H.-J. Wang, E. Oldfield, Science 2008, 319, 1391-1394.
28. G. Y. Liu, A. Essex, J. T. Buchanan, V. Datta, H. M. Hoffman, J. F. Bastian, J. Fierer, V. Nizet, J. Exp. Med. 2005, 202, 209-215.
29. a) A. W. Segal, Annu. Rev. Immunol. 2005, 23, 197-223;
30. b) F. C. Fang, Nat. Rev. Microbiol. 2004, 2, 820-832;
31. c) J. P. Kehrer, Toxicology 2000, 149, 43-50;
32. d) D. B. Graham, C. M. Robertson, J. Baut ista, F. Mascarenhas, M. J. Diacovo, V. Montgrain, S. K. Lam, V. Cremasco, W. M. Dunne, R. Faccio, C. M. Coopersmith, W. Swat, J. Clin. Invest. 2007, 117, 3445-3452.
33. A. Clauditz, A. Resch, K.-P. Wieland, A. Peschel, F. Götz, Infect. Immun. 2006, 74, 4950-4953.
34. a) A. Pelz, K.-P. Wieland, K. Putzbach, P. Hentschel, K. Albert, F. Götz, J. Biol. Chem. 2005, 280, 32493-32498;
35. b) B. Wieland, C. Feil, E. Gloria-Maercker, G. Thumm, M. Lechner, J. M. Bravo, K. Poralla, F. Götz, J. Bacteriol. 1994, 176, 7719-7726.
36. J. H. Marshall, G. J. Wilmoth, J. Bacteriol. 1981, 147, 900-913.
37. E. I. Wilding, J. R. Brown, A. P. Bryant, A. F. Chalker, D. J. Holmes, K. A. Ingraham, S. Iordanescu, C. Y. So, M. Rosenberg, M. N. Gwynn, J. Bacteriol. 2000, 182, 4319-4327.
38. 55 lipid carrier and suppression of staphyloxanthin production: M. Kuroda, S. Nagasaki, T. Ohta, J. Antimicrob. Chemother. 2007, 59, 425-432.
39. All work in reference [10] was carried out with racemic compounds. However, the authors have meanwhile tested the pure R and S enantiomers of 12 in the enzyme and in cells. The S form was far more active in both cases: E. Oldfield, personal communication, 2008.
40. The racemate of 12 was used in crystallization. As it is difficult to unambiguously discriminate between phosphorous and sulfur in X-ray crystallography, it remains uncertain whether the bound form was the less active R or indeed the more active S enantiomer of 12.
41. The synthesis of (S)-(-)-3-phenoxy-α- phosphonobenzenebutanesulfonic acid, tripotassium salt (12) was carried out in 88% ee by asymmetric alkylation: D. R. Magnin, S. A. Biller, J. K. Dickson, Jr., R. M. Lawrence, R. B. Sulsky (E. R. Squibb and Sons, Inc., USA), EP595635, 1994, [Chem. Abstr. 1994, 121, 157872].
42. a) A. Sharma, P. H. Slugg, J. L. Hammett, W. J. Jusko, J. Clin. Pharmacol. 1998, 38, 1116-1121;
43. b) A. Sharma, P. H. Slugg, J. L. Hammett, W. J. Jusko, Pharm. Res. 1998, 15, 1782-1786;
44. c) A. Sharma, P. H. Slugg, J. L. Hammett, W. J. Jusko, Pharm. Res. 1998, 14, Suppl. (S239);
45. d) O. P. Flint, B. A. Masters, R. E. Gregg, S. K. Durham, Toxicol. Appl. Pharmacol. 1997, 145, 91-98.
46. See reference [21a]: Healthy volunteers received a daily oral dose of 10 mg for 2 weeks, or a daily oral dose of 25, 50, 100, or 200 mg for 4 weeks.
47. a) D. B. Ross, N. Engl. J. Med. 2007, 356, 1601-1604;
48. b) FDA: http://www.fda.gov/cder/guidance/index. htm#clinical%20antimicrobial (last access: July 2, 2008).
49. In October 2007, the FDA released draft guidance which considered non-inferiority trials unacceptable for self-resolving respiratory tract infections such as acute bacterial sinusitis, exacerbation of chronic bronchitis, and otitis media; an extension to community acquired pneumonia (CAP) is under discussion.
50. Leading Edge editorial, Lancet Infect. Dis. 2008, 8, 209.